Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 307

1.

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD.

Arch Intern Med. 2005 Jan 24;165(2):181-6.

PMID:
15668364
[PubMed - indexed for MEDLINE]
2.

Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S392-400.

PMID:
12416789
[PubMed - indexed for MEDLINE]
Free Article
3.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
[PubMed - indexed for MEDLINE]
Free Article
4.

Underutilization of preventive strategies in patients receiving NSAIDs.

Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.

Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31.

PMID:
14585915
[PubMed - indexed for MEDLINE]
Free Article
6.

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.

Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.

Arthritis Rheum. 2006 May;54(5):1378-89.

PMID:
16645966
[PubMed - indexed for MEDLINE]
Free Article
7.

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.

Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A.

Arch Intern Med. 2005 Jan 24;165(2):189-92.

PMID:
15668365
[PubMed - indexed for MEDLINE]
8.

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.

Arch Intern Med. 2003 Feb 24;163(4):481-6.

PMID:
12588209
[PubMed - indexed for MEDLINE]
9.

Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores.

Shaya FT, Samant N, Skolasky R, Saunders E.

Expert Rev Pharmacoecon Outcomes Res. 2005 Oct;5(5):625-32. doi: 10.1586/14737167.5.5.625.

PMID:
19807588
[PubMed]
10.

National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.

Dai C, Stafford RS, Alexander GC.

Arch Intern Med. 2005 Jan 24;165(2):171-7.

PMID:
15668363
[PubMed - indexed for MEDLINE]
11.

Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.

Joshua FF, Oakley SP, Major GA.

Intern Med J. 2004 Apr;34(4):153-61.

PMID:
15086694
[PubMed - indexed for MEDLINE]
12.

"Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.

Bennett K, Teeling M, Feely J.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):645-9. Epub 2003 Aug 27.

PMID:
12942226
[PubMed - indexed for MEDLINE]
14.

Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.

Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.

Arthritis Res Ther. 2005;7(2):R333-42. Epub 2005 Jan 17.

PMID:
15743481
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.

Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH.

Arch Intern Med. 2008 Jun 9;168(11):1219-24. doi: 10.1001/archinte.168.11.1219.

PMID:
18541831
[PubMed - indexed for MEDLINE]
16.

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.

Layton D, Hughes K, Harris S, Shakir SA.

Rheumatology (Oxford). 2003 Nov;42(11):1354-64. Epub 2003 Jul 16.

PMID:
12867585
[PubMed - indexed for MEDLINE]
Free Article
17.

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.

Ann Intern Med. 2005 Feb 1;142(3):157-64.

PMID:
15684203
[PubMed - indexed for MEDLINE]
18.

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.

PMID:
12914871
[PubMed - indexed for MEDLINE]
19.

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force.

Ann Intern Med. 2007 Mar 6;146(5):376-89. Review.

PMID:
17339623
[PubMed - indexed for MEDLINE]
20.

Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database.

Schnitzer TJ, Kong SX, Mavros PP, Straus WL, Watson DJ.

Clin Ther. 2001 Dec;23(12):1984-98.

PMID:
11813933
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk